Skip to content

Time Restricted Feeding in Male Runners

The Effects of Four Weeks of Intermittent Fasting on Resting Energy Expenditure, Satiety Hormones, Body Composition, and Performance in Competitive Runners

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03569852
Enrollment
21
Registered
2018-06-26
Start date
2018-07-15
Completion date
2020-03-24
Last updated
2020-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Athletic Performance, Cardiovascular Risk Factor, Fasting, Intermittent Fasting, Resting Energy Expenditure

Brief summary

This is a cross-over intervention study designed to evaluate how four weeks of time restricted feeding (16 hours fasting and 8 hours feeding), compared to four weeks of a more traditional eating pattern (12 hours fasting and 12 hours feeding), affects resting energy expenditure, subjective and biochemical markers of satiety and hunger, body composition, cardiovascular health, substrate utilization and fitness in male competitive runners.

Detailed description

Weight loss and improvements in body composition (increasing muscle mass and decreasing fat mass) are common goals for both dieters and athletes. Although a traditional method of achieving this has been accomplished through caloric restriction, an alternate method that is becoming increasingly popular is fasting. Fasting is described as the absence of food and/or calorie-containing beverage consumption for a period of time. The majority of people fast for 8-10 hours daily, which occurs during the overnight period when people are asleep Intermittent fasting, specifically time-restricted feeding (TRF), has recently gained popularity because it is a more sustainable means of practicing fasting and it has been shown to enhance the loss of fat mass with or without caloric restriction. It has also been shown to enhance overall health due to reports of reduced fasting glucose, insulin resistance, triglycerides, and reduced total and low-density lipoprotein (LDL) cholesterol levels in obese women. Despite its growing popularity among athletes, there is scarce research on how adhering to this type of diet pattern affects athletic performance and other biochemical markers related to health. The participants in this study will be randomly assigned to either a traditional (12/12) or a time restrictive (16/8) eating pattern in a crossover design. Each pattern will last for four weeks with a minimum two week washout in between, and the participants will consume the same calorie and macronutrient amounts based on recommendations made by the American College of Sports Medicine (ACSM) for both eating patterns. The 12/12 pattern will require subjects to consume 5 meals (breakfast, lunch, dinner, and two snacks) per day within a 12 hour period suggested to be around 8am, 10am, 12pm, 3pm, and 7pm. The 16/8 pattern will require subjects to consume 3 meals in an 8-hour period suggested to be around 12pm, 3pm, and 7pm. Subjects may only consume water, unsweetened coffee, or unsweetened tea (no artificial sweeteners) during their periods of fasting. Subjects will perform all exercise in the morning before 8 am in the fasted state. Subjects will visit the Western Human Nutrition Research Center (WHNRC) for test days at baseline (study day 1), after four weeks of the first dietary intervention (study day 28), and at the start (study day 43) and end of the second dietary intervention (study day 70), for a total of 4 test days over the duration of 10 weeks.

Interventions

BEHAVIORALTime Restrictive Feeding

Volunteers will adhere to a form of time restrictive feeding, 16 hours fasting and 8 hours eating per day.

BEHAVIORALTraditional Eating Pattern

Volunteers will adhere to a more traditional eating pattern, 12 hours fasted and 12 hours eating per day.

Sponsors

University of California, Davis
CollaboratorOTHER
USDA, Western Human Nutrition Research Center
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Competitive runners who have been actively training for 3 or more years * Weigh a minimum of 110 lbs * Training 4-6 times per week and run a minimum of 20 miles per week * Competed in a race within past 12 months at a distance of 5 - 26.1 km * Willing to repeat same monthly training protocol during two 4-week interventions * VO2max range of 40-70 ml/kg/min

Exclusion criteria

* Smoker * Take medications that have cardiovascular or metabolic effects * Taking dietary supplements * Following a restrictive diet including restricting calories or carbohydrates * Evidence of an eating disorder * Major injuries in past 3 months * Chronic disease that affects bone health, metabolism or the cardiorespiratory system * Present with any contra-indication to exercise testing (cardiovascular abnormalities) as evaluated by study physician

Design outcomes

Primary

MeasureTime frameDescription
Change in resting energy expenditureStudy day 1, 28, 43 and 70Resting energy expenditure will be measured using a metabolic cart

Secondary

MeasureTime frameDescription
Change in substrate utilization during exerciseStudy day 1, 28, 43 and 70Carbohydrate and fat utilized for energy will be measured using a metabolic cart
Change in cardiovascular fitnessStudy day 1, 28, 43 and 70Time to run a 10 kilometer time trial on a treadmill expressed in minutes
Change in perceived feelings of hunger and fullnessStudy day 1, 28, 43 and 70Perceived hunger and fullness will be measured using a visual analog scale. Responses will be a mark on an unsegmented line from 0 or not at all to 5 or extremely.
Change in glucagon, a biomarker of hunger and satietyStudy day 1, 28, 43 and 70Fasting plasma will be analyzed for glucagon (pmol/L) as measured by enzyme-linked immunoabsorbant assay
Change in leptin, a biomarker of hunger and satietyStudy day 1, 28, 43 and 70Fasting plasma will be analyzed for leptin (pmol/L) as measured by enzyme-linked immunoabsorbant assay
Change in ghrelin, a biomarker of hunger and satietyStudy day 1, 28, 43 and 70Fasting plasma will be analyzed for ghrelin (pmol/L) as measured by enzyme-linked immunoabsorbant assay
Change in insulinStudy day 1, 28, 43 and 70Fasting plasma will be analyzed for insulin (pmol/L) as measured by enzyme-linked immunoabsorbant assay
Change in body compositionStudy day 1, 28, 43 and 70Body composition, including fat mass and lean body mass, will be measured by dual-energy x-ray absorptiometry (DEXA) and expressed in kilograms (kg).
Change in HDL cholesterol, a biomarker of cardiovascular healthStudy day 1, 28, 43 and 70Fasting serum will be analyzed for HDL cholesterol (mmol/L) by Piccolo analyzer
Change in LDL cholesterol, a biomarker of cardiovascular healthStudy day 1, 28, 43 and 70Fasting serum will be analyzed for LDL cholesterol (mmol/L) by Piccolo analyzer
Change in very low-density lipoprotein (VLDL), a biomarker of cardiovascular healthStudy day 1, 28, 43 and 70Fasting serum will be analyzed for very low-density lipoprotein (VLDL) cholesterol (mmol/L) by Piccolo analyzer
Change in triglycerides, a biomarker of cardiovascular healthStudy day 1, 28, 43 and 70Fasting serum will be analyzed for triglycerides (mmol/L) by Piccolo analyzer
Change in alanine aminotransferase, a biomarker of cardiovascular healthStudy day 1, 28, 43 and 70Fasting serum will be analyzed for alanine aminotransferase (IU/L) by Piccolo analyzer
Change in aspartate aminotransferase, a biomarker of cardiovascular healthStudy day 1, 28, 43 and 70Fasting serum will be analyzed for aspartate aminotransferase (IU/L) by Piccolo analyzer
Change in glucoseStudy day 1, 28, 43 and 70Fasting serum will be analyzed for glucose (mmol/L) by Piccolo analyzer
Change in total cholesterol, a biomarker of cardiovascular healthStudy day 1, 28, 43 and 70Fasting serum will be analyzed for total cholesterol (mmol/L) by Piccolo analyzer

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026